CY1107438T1 - Παραγωγα καρβοξυλικου οξεος, τα οποια παρεμποδιζουν την συνδεσιν ιντεγκρινων εις τους υποδοχεις των - Google Patents
Παραγωγα καρβοξυλικου οξεος, τα οποια παρεμποδιζουν την συνδεσιν ιντεγκρινων εις τους υποδοχεις τωνInfo
- Publication number
- CY1107438T1 CY1107438T1 CY20081100253T CY081100253T CY1107438T1 CY 1107438 T1 CY1107438 T1 CY 1107438T1 CY 20081100253 T CY20081100253 T CY 20081100253T CY 081100253 T CY081100253 T CY 081100253T CY 1107438 T1 CY1107438 T1 CY 1107438T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inhibit
- integrinal
- acceptances
- connection
- carboxylic acid
- Prior art date
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13297199P | 1999-05-07 | 1999-05-07 | |
| EP00937527A EP1176956B1 (en) | 1999-05-07 | 2000-05-05 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107438T1 true CY1107438T1 (el) | 2012-12-19 |
Family
ID=22456441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100253T CY1107438T1 (el) | 1999-05-07 | 2008-03-05 | Παραγωγα καρβοξυλικου οξεος, τα οποια παρεμποδιζουν την συνδεσιν ιντεγκρινων εις τους υποδοχεις των |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1176956B1 (enExample) |
| JP (1) | JP5132855B2 (enExample) |
| AT (1) | ATE383153T1 (enExample) |
| AU (1) | AU5267900A (enExample) |
| CA (1) | CA2373360C (enExample) |
| CY (1) | CY1107438T1 (enExample) |
| CZ (1) | CZ303312B6 (enExample) |
| DE (1) | DE60037726T2 (enExample) |
| DK (1) | DK1176956T3 (enExample) |
| ES (1) | ES2296625T3 (enExample) |
| IL (2) | IL146311A0 (enExample) |
| IN (1) | IN2001KN01110A (enExample) |
| MX (1) | MXPA01011340A (enExample) |
| NO (1) | NO324421B1 (enExample) |
| NZ (1) | NZ515248A (enExample) |
| PL (1) | PL205322B1 (enExample) |
| RO (1) | RO122246B1 (enExample) |
| RU (1) | RU2263109C2 (enExample) |
| SI (1) | SI20744B (enExample) |
| SK (1) | SK286696B6 (enExample) |
| TR (2) | TR200201920T2 (enExample) |
| WO (1) | WO2000067746A1 (enExample) |
| ZA (1) | ZA200108774B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
| SI21096B (sl) * | 2001-10-09 | 2012-05-31 | Encysive Pharmaceuticals Inc | Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje |
| AP1822A (en) * | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| MXPA05000069A (es) | 2002-06-28 | 2005-04-11 | Vertex Pharma | Inhibidores de caspasa y uso de los mismos. |
| US7122580B2 (en) | 2002-08-09 | 2006-10-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| US20070060608A1 (en) * | 2002-11-08 | 2007-03-15 | Encysive Pharmaceuticals Inc. | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds |
| US7612091B2 (en) | 2002-12-20 | 2009-11-03 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| EP1660439A2 (en) | 2003-08-08 | 2006-05-31 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005014534A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
| CA2680366C (en) * | 2007-03-09 | 2016-06-21 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
| CA2677049A1 (en) | 2007-08-01 | 2009-02-05 | Sionex Corporation | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
| MX2011011326A (es) * | 2009-04-27 | 2012-02-13 | Elan Pharm Inc | Antagonistas de piridinona de las integrinas alfa-4. |
| WO2012033548A2 (en) * | 2010-09-07 | 2012-03-15 | E. I. Du Pont De Nemours And Company | Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles |
| AU2010292400B2 (en) | 2009-09-09 | 2016-09-08 | Fmc Corporation | Herbicidal pyrimidone derivatives |
| SI2810937T1 (sl) * | 2012-01-31 | 2017-01-31 | Daiichi Sankyo Company, Limited | Derivat piridona |
| EP3046920B1 (en) | 2013-09-20 | 2021-08-04 | BioMarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| KR20170052526A (ko) | 2014-03-13 | 2017-05-12 | 프로테나 바이오사이언시즈 리미티드 | 다발성 경화증에 대한 병용 치료 |
| CN110452216B (zh) * | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US10246451B2 (en) * | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| EP3615087B1 (en) | 2017-04-28 | 2023-09-06 | Texas Children's Hospital | Targeting nanoparticles |
| CA3090270A1 (en) * | 2018-02-02 | 2019-08-08 | Genentech, Inc. | Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same |
| JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４β７インテグリンの阻害のための化合物 |
| CN119462635A (zh) | 2018-10-30 | 2025-02-18 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| KR20220047323A (ko) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2614189A1 (de) * | 1976-04-02 | 1977-10-20 | Hoechst Ag | Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung |
| US5220017A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
| ATE195117T1 (de) * | 1993-03-31 | 2000-08-15 | Searle & Co | 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren |
| AU672699B2 (en) * | 1993-06-30 | 1996-10-10 | Sankyo Company Limited | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses |
| US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| JPH07304755A (ja) * | 1994-05-12 | 1995-11-21 | Yamanouchi Pharmaceut Co Ltd | 縮合ジアゼピン誘導体 |
| US5610296A (en) * | 1994-12-05 | 1997-03-11 | G. D. Searle & Co. | Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| JP2000510700A (ja) * | 1996-05-15 | 2000-08-22 | ジー．ディー．サール アンド カンパニー | 抗血小板化合物の血中レベルを追跡するための方法と試薬 |
| JP2001500875A (ja) * | 1996-09-18 | 2001-01-23 | メルク エンド カンパニー インコーポレーテッド | 心臓血管系疾患関連の危険性を減らす併用治療法 |
| US6025358A (en) * | 1998-06-11 | 2000-02-15 | G. D. Searle & Co. | Double prodrugs of potent GP IIb/IIIa antagonists |
| HK1040076A1 (zh) * | 1998-09-21 | 2002-05-24 | 希雷生物化学有限公司 | 作为整联蛋白抑制剂的喹嗪酮 |
-
2000
- 2000-05-05 TR TR2002/01920T patent/TR200201920T2/xx unknown
- 2000-05-05 WO PCT/US2000/012303 patent/WO2000067746A1/en not_active Ceased
- 2000-05-05 RO ROA200101210A patent/RO122246B1/ro unknown
- 2000-05-05 IL IL14631100A patent/IL146311A0/xx active IP Right Grant
- 2000-05-05 RU RU2001133360/04A patent/RU2263109C2/ru not_active IP Right Cessation
- 2000-05-05 DE DE60037726T patent/DE60037726T2/de not_active Expired - Lifetime
- 2000-05-05 AT AT00937527T patent/ATE383153T1/de active
- 2000-05-05 TR TR2001/03178T patent/TR200103178T2/xx unknown
- 2000-05-05 SK SK1608-2001A patent/SK286696B6/sk not_active IP Right Cessation
- 2000-05-05 JP JP2000616772A patent/JP5132855B2/ja not_active Expired - Fee Related
- 2000-05-05 NZ NZ515248A patent/NZ515248A/xx not_active IP Right Cessation
- 2000-05-05 EP EP00937527A patent/EP1176956B1/en not_active Expired - Lifetime
- 2000-05-05 MX MXPA01011340A patent/MXPA01011340A/es active IP Right Grant
- 2000-05-05 CZ CZ20013963A patent/CZ303312B6/cs not_active IP Right Cessation
- 2000-05-05 PL PL351396A patent/PL205322B1/pl unknown
- 2000-05-05 AU AU52679/00A patent/AU5267900A/en not_active Abandoned
- 2000-05-05 DK DK00937527T patent/DK1176956T3/da active
- 2000-05-05 SI SI200020021A patent/SI20744B/sl not_active IP Right Cessation
- 2000-05-05 ES ES00937527T patent/ES2296625T3/es not_active Expired - Lifetime
- 2000-05-05 CA CA2373360A patent/CA2373360C/en not_active Expired - Lifetime
- 2000-11-16 IN IN1110KON2001 patent/IN2001KN01110A/en unknown
-
2001
- 2001-10-24 ZA ZA200108774A patent/ZA200108774B/en unknown
- 2001-11-01 IL IL146311A patent/IL146311A/en not_active IP Right Cessation
- 2001-11-06 NO NO20015418A patent/NO324421B1/no not_active IP Right Cessation
-
2008
- 2008-03-05 CY CY20081100253T patent/CY1107438T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107438T1 (el) | Παραγωγα καρβοξυλικου οξεος, τα οποια παρεμποδιζουν την συνδεσιν ιντεγκρινων εις τους υποδοχεις των | |
| EP1203766B8 (en) | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | |
| PL346220A1 (en) | Compounds that inhibit the binding of integrins to their receptors | |
| IL146312A0 (en) | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | |
| ATE420876T1 (de) | Propansäurederivate die die bindung von integrinen an ihre rezeptoren hemmen | |
| CA2361285A1 (en) | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |